N Engl J Med 2015 Jun 25
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Related Questions
New answer by Medical Oncologist at Duke University School of Medicine (December 13, 2016)
The answer to this question depends on the patient's molecular diagnostics and prior therapy. I'll assume FOLFOX/XELOX-bev. If KRAS WT, I'll assume followed by FOLFIRI-EGFRi. ...
Would you choose to use IO or BRAF directed therapy based on BEACON? Or would you continue to use cytotoxic chemotherapy?
New answer by (March 6, 2020)
I agree with @Anita Turk and would utilize IO in the second line for BRAF-mutant MSI-H colorectal cancer, and cetuximab + encorafenib in the third line setting. I also favor f...